Twist Bioscience (TWST) Accumulated Expenses (2018 - 2026)

Twist Bioscience (TWST) has reported Accumulated Expenses for 9 consecutive years, with $27.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 37.98% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $27.0 million (up 37.98% YoY), while the FY2025 annual figure was $31.3 million, down 7.02% from the prior year.
• Accumulated Expenses grew to $27.0 million in Q1 2026 per TWST's latest filing, from $23.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $33.6 million in Q3 2024 and bottomed at $10.2 million in Q3 2022.
• Historically, Accumulated Expenses has averaged $21.9 million across 5 years, with a median of $23.3 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 387.22% — and 2023, when it sank 62.77%.
• Twist Bioscience's Accumulated Expenses stood at $23.3 million in 2022, then retreated by 10.7% to $20.8 million in 2023, then gained by 4.59% to $21.7 million in 2024, then rose by 7.65% to $23.4 million in 2025, then advanced by 15.37% to $27.0 million in 2026.
• Business Quant data shows TWST's Accumulated Expenses at $27.0 million in Q1 2026, $23.4 million in Q4 2025, and $31.3 million in Q3 2025.